نمایش پرونده ساده آیتم

dc.contributor.authorPishva, H
dc.contributor.authorAmini, M
dc.contributor.authorEshraghian, MR
dc.contributor.authorHosseini, S
dc.contributor.authorMahboob, SA
dc.date.accessioned2018-08-26T08:53:04Z
dc.date.available2018-08-26T08:53:04Z
dc.date.issued2012
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53872
dc.description.abstractBackground: Fatty acid binding protein 2 (FABP2) and peroxisome proliferator-activated receptor ? (PPAR?) are involved in cellular uptake and metabolism of fatty acids. Polymorphism of FABP2 and PPAR? may influence plasma levels of fatty acids in those who take supplemental eicosapentaenoic acid (EPA). The purpose of this study was to study the potential associations between the Ala54/Thr polymorphism in FABP2 protein and the Leu162/Val in exon 5 and G/C in intron 7 of PPAR? with plasma fatty acids composition after EPA supplementation.Methods: Twenty three FABP2 Ala54 and twenty three Thr54 carriers with hypertriglyceridemia were enrolled in this study. Participants took 2 g of pure EPA daily for 8 wks. Plasma fatty acids composition was determined and changes from the baseline were measured. Results: Although EPA supplementation increased the level of plasma EPA and ?-3 fatty acids in both carriers of FABP2 and PPAR? genes, these effects were more pronounced in Thr54 and Val162 carriers. EPA supplementation decreased the level of some n-6 fatty acids such as arachidonic acid.Conclusion: EPA consumption has more favorable effects on blood n-3 fatty acids and can change the level of plasma n-3 fatty acids, particularly EPA. Because the FABP2 Thr54 polymorphism appears to be prevalent in hypertriglyceridemic subjects, increasing EPA intake in these subjects could be an effective strategy for preventing cardiovascular diseases. Finally, diets and micronutrient recommendations should be individualized for high risk people. © 2012 Pishva et al.; licensee BioMed Central Ltd.
dc.language.isoEnglish
dc.relation.ispartofJournal of Diabetes and Metabolic Disorders
dc.subject11 ecosenoic acid
dc.subject11, 14 ecosadienoic acid
dc.subject15 tetracosenoic acid
dc.subjectalanine
dc.subjectarachidic acid
dc.subjectarachidonic acid
dc.subjectbehenic acid
dc.subjectdihomo gamma linolenic acid
dc.subjectfatty acid binding protein 2
dc.subjectgamma linolenic acid
dc.subjecticosapentaenoic acid
dc.subjectleucine
dc.subjectlinoleic acid
dc.subjectmiristic acid
dc.subjectmonounsaturated fatty acid
dc.subjectoleic acid
dc.subjectomega 3 fatty acid
dc.subjectomega 6 fatty acid
dc.subjectpalmitic acid
dc.subjectperoxisome proliferator activated receptor alpha
dc.subjectpolyunsaturated fatty acid
dc.subjectsaturated fatty acid
dc.subjectstearic acid
dc.subjectthreonine
dc.subjectunclassified drug
dc.subjectvaline
dc.subjecticosapentaenoic acid
dc.subjectarticle
dc.subjectdrug effect
dc.subjectexon
dc.subjectfatty acid blood level
dc.subjectgenetic association
dc.subjectgenetic polymorphism
dc.subjectgenotype
dc.subjecthuman
dc.subjecthypertriglyceridemia
dc.subjectintron
dc.subjectlipid composition
dc.subjectplasma fatty acids composition
dc.subjectsupplementation
dc.subjecttreatment duration
dc.subjectamino acid substitution
dc.subjectArticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdiet supplementation
dc.subjectdrug mechanism
dc.subjectfatty acid blood level
dc.subjectgenetic polymorphism
dc.subjectgenetic variability
dc.subjectheterozygote
dc.subjecthypertriglyceridemia
dc.subjecttreatment response
dc.titleEffects of EPA supplementation on plasma fatty acids composition in hypertriglyceridemic subjects with FABP2 and PPAR? genotypes
dc.typeBook Chapter
dc.citation.volume11
dc.citation.issue1
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1186/2251-6581-11-25


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم